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Abstract
Glioblastoma multiforme (GBM) is a deadly cancer that possesses an intrinsic resistance to pro-apoptotic insults,
such as conventional chemotherapy and radiotherapy, and diffusely invades the brain parenchyma, which renders
it elusive to total surgical resection. We found that fusicoccin A, a fungal metabolite from Fusicoccum amygdali,
decreased the proliferation and migration of human GBM cell lines in vitro, including several cell lines that exhibit
varying degrees of resistance to pro-apoptotic stimuli. The data demonstrate that fusicoccin A inhibits GBM cell pro-
liferation by decreasing growth rates and increasing the duration of cell division and also decreases two-dimensional
(measured by quantitative video microscopy) and three-dimensional (measured by Boyden chamber assays) migra-
tion. These effects of fusicoccin A treatment translated into structural changes in actin cytoskeletal organization and
a loss of GBM cell adhesion. Therefore, fusicoccin A exerts cytostatic effects but low cytotoxic effects (as demon-
strated by flow cytometry). These cytostatic effects can partly be explained by the fact that fusicoccin inhibits the
activities of a dozen kinases, including focal adhesion kinase (FAK), that have been implicated in cell proliferation
and migration. Overexpression of FAK, a nonreceptor protein tyrosine kinase, directly correlates with the invasive
phenotype of aggressive human gliomas because FAK promotes cell proliferation and migration. Fusicoccin A led
to the down-regulation of FAK tyrosine phosphorylation, which occurred in both normoxic and hypoxic GBM cell
culture conditions. In conclusion, the current study identifies a novel compound that could be used as a chemical
template for generating cytostatic compounds designed to combat GBM.
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Introduction
Glioblastomamultiforme (GBM;World Health Organization grade IV)
is the most common malignant primary brain tumor in adults and
children and is associated with a dismal prognosis. The mean survival
time after the current standard treatment that includes a combination
of neurosurgery, radiotherapy, and concomitant chemotherapy with
temozolomide (TMZ) is only 15 months [1–3]. The low survival rate
for patients with GBM reflects the inability to achieve total surgical
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resection, mainly because GBM cells possess the ability to invade the
surrounding normal brain and have a high propensity for recurrence
[2–5]. GBMs are characterized by a number of genetic and signaling
abnormalities that ultimately lead to uncontrolled cellular prolifera-
tion and invasion, angiogenesis, necrosis, and resistance to cytotoxic
therapies [2–5]. Among these aberrancies are an abnormal activation of
the phosphatidylinositol 3-kinase (PI3K)/AKT and Ras/Raf/mitogen-
activated protein kinase (MAPK) signal transduction pathways [2].
Therefore, to improve the prognosis of patients with GBM, it is essential
to find novel therapeutic agents that can manage the growth, invasion,
and progression of these tumor cells by interfering with signaling mole-
cules or pathways that are critical for themalignant phenotype of gliomas,
including GBMs. Numerous clinical trials are currently investigating
the benefits of synthetic agents called targeted therapeutics [6–8].
Natural products are a valuable resource that could yield novel effi-
cacious anticancer agents [9,10]. Various attempts have been made to
treat GBM patients with paclitaxel [11], a microtubule inhibitor, or
with irinotecan [12], a topoisomerase inhibitor, but these drugs have
had limited success, even when locally delivered to bypass the blood-
brain barrier. These compounds are cytotoxic and rapidly induce GBM
chemoresistance processes, including the activation of the multidrug
resistance phenotype [13]. In our research programs, we are searching
for novel natural compounds that display 1) growth inhibitory effects
in malignant glioma cells that exhibit varying degrees of resistance to
pro-apoptotic stimuli, 2) cytostatic rather than cytotoxic effects, and
3) bioselectivity between normal and tumor glial cells. The current
study shows that fusicoccin A fits these various criteria.
Fusicoccin A is the α-D-glucopyranoside of a carbotricyclic diter-
pene (Figure 1) that is the main phytotoxin produced by Fusicoccum
amygdali, the causative fungal agent of peach and almond canker
[14]. Several reports have previously described the biologic effects of
fusicoccin A in plant and mammalian cells. Fusicoccin A activates
Figure 1. Physicochemical stability of fusicoccin A. The determination of fusicoccin A (1) physicochemical stability and the identification of
its two major degradation products [3′-O-deacetyl fusicoccin (2) and 19-O-deacetyl fusicoccin (3)] when maintained for 3 days (B) at 37°C in
MEM compared to day 0 (A).
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the plasma membrane H+-ATPase by stabilizing its binding to 14-3-3
proteins, which results in water loss and the wilting of infected plants
[15]. Bunney et al. [16] demonstrated that fusicoccin A–related signal-
ing reveals 14-3-3 protein function as a novel step in left-right pattern-
ing during amphibian embryogenesis. Fusicoccin A also targets 14-3-3
proteins in cancer cells [17] and it promotes isoform-specific expression
of 14-3-3 proteins in human gliomas [18]. Takahashi et al. [17] found
that these 14-3-3 proteins play a critical role in serine/threonine kinase–
dependent signaling pathways through protein-protein interactions
with multiple phosphorylated ligands. Fusicoccin A also induces apop-
tosis in tumor cells by activating the tumor necrosis factor–related
apoptosis-inducing ligand pathway when it is applied to cells after or
combined with interferon-α priming [19]. Here, we report the bio-
selective effects of fusicoccin A between normal and tumor glial cells,
with fusicoccin A–mediated targeting of several kinases (that are impli-
cated in the actin cytoskeleton organization) and a special emphasis on
focal adhesion kinase (FAK), which is implicated in GBM cell prolif-
eration and migration phenotypes.
Materials and Methods
Fusicoccin A, 3′-O-Deacetyl Fusicoccin A, and
19-O-Deacetyl Fusicoccin A
Fusicoccin A was harvested from F. amygdali as reported previously
[20,21]. Fusicoccin A samples were purified by column chromatography
[eluent CHCl3-iso-PrOH (9:1)] and crystallized from EtOAc–n-hexane
as detailed previously [21]. The electrospray ionization–mass spectrom-
etry (ESI-MS) spectrum of the major degradation product revealed a
molecular sodium cluster at 661 m/z, which corresponded to 3′-O-
deacetyl fusicoccin A and this result was confirmed by the 1H nuclear
magnetic resonance (NMR) and electron impact–mass spectrometry
(EI-MS) spectra. The minor degradation product’s ESI-MS spectrum
displayed sodium and potassium cluster ions at m/z 661 and 677,
respectively. These data completed by 1H NMR analyses enabled the
identification of the structure as 19-O-deacetyl fusicoccin A.
To obtain sufficient amounts of these two degradation products
to test their in vitro growth inhibitory concentrations in glioma cell
lines (see below), both products were obtained from the deacetyla-
tion of fusicoccin A. Fusicoccin A (100 mg) was dissolved in 250 ml
of MeOH and left at 37°C for 1 week. Next, the solvent was evapo-
rated under reduced pressure and the residue was purified by pre-
parative thin-layer chromatography (TLC) and eluted with solvent
system A (see below) to yield 3′-O- and 19-O-deacetylfusicoccin A as
amorphous solids (70 and 9 mg, respectively).
Physicochemical Stability Analyses
Fusicoccin A stability inminimal essential cell culturemedium (MEM)
was characterized at 37°C for 3 days. Fusicoccin A (100 μg/ml) was
prepared by diluting a DMSO stock solution in MEM (Invitrogen,
Merelbeke, Belgium). After 3 days of incubation at 37°C, the solution
was diluted with the appropriate solvent (see below) at 1 μg/ml final
concentration for analysis. For improved observation of the degradation
peaks, the volume injected into high-performance liquid chromatogra-
phy (HPLC) D3 (V inj = 2X) was doubled compared to D0 (V inj = 1X).
The chromatograms were recorded on Agilent Technologies 1200 series
with a UV-VIS detector. The column used for this analysis was a C-18
HD, the solvent was CH3OH/H2O (7:3), the flow rate was 0.5 ml/min,
and λ = 220 nm. Analytical and preparative TLCs were performed on
silica gel (Merck, Darmstadt, Germany; Kieselgel 60 F254, 0.25 and
0.50mm, respectively). The spots were visualized by exposure toUV light
and/or by first spraying them with a 10% H2SO4 solution in MeOH
and then with 5% phosphomolybdic acid in ethanol, which was followed
by heating at 110°C for 10 minutes. Solvent system (A) was CHCl3-i-
PrOH (93:7). 1H NMR spectra were recorded at 400 MHz in CDCl3
by Bruker spectrometers. ESI-MS spectra were recorded on Agilent
Technologies 1100 series quadrupole 6120 and the EI-MS spectra were
taken at 70 eV on a QP 5050 Shimadzu spectrometer.
Cell Lines, Culture Conditions, and Transfection
Cancer cell lines were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The U373-MG (ATCC code
HTB-17) human glioblastoma, the Hs683 (ATCC code HTB-138)
human oligodendroglioma, and the B16F10 (ATCC code CRL-
6475) mouse melanoma cell lines were cultured in RPMI (Invitrogen)
culture media supplemented with 10% heat-inactivated fetal calf serum
(FCS; Invitrogen), 4 mM glutamine, 100 μg/ml gentamicin, and
penicillin-streptomycin (200 U/ml and 200 μg/ml; Invitrogen) at
5% CO2, 21% O2, and 37°C. Hypoxia (1% O2) was achieved as pre-
viously described [22]. For FAK overexpression, pCMV6-PTK2 (FAK)
and pCMV6-XL4 (control) fromOriGene (Rockville, MD) were trans-
fected into U373-MG cells with TurboFect (Fermentas, Waltham,
MA) as previously described [23]. Transfected cells were selected with
G418 (Invitrogen) at 300 μg/ml during 2 weeks. All cancer cell lines
used in this work have been previously cultured with DMSO concen-
trations up to 5%without anymodifications in their growth levels when
compared to control cells.
Normal astrocytes were obtained from neonatal nuclear magnetic
resonance imaging (NMRI) mouse cortices that were freed of
meninges, minced into small pieces of tissue with microscissors, and
then suspended in MEM (Invitrogen) supplemented with 6 g/l glucose
and 10% FCS (Invitrogen). The cell suspension was then filtered
through 225- and 25-μm pore filters. The filtered cell suspension
was plated on an uncoated T25 flask for 72 hours. The medium
was then changed and the cells were grown until confluence. Control
astrocytes were exposed to the percentages of DMSO used in fusicoccin
A–related treated conditions.
Cell Growth Inhibition Assay
The colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) viability assay (Sigma, Bornem, Belgium) was used
to determine the overall growth rate of each cell line as previously
described [24]. The number of living cells was determined after 72 hours
of culture in the presence of fusicoccin A, 3′-O-deacetyl fusicoccin A,
or 19-O-deacetyl fusicoccin A. Fusicoccin A was also tested on mouse
astrocytes. Each experimental condition was performed in triplicate.
To investigate whether fusicoccin A–induced growth inhibitory
effects in glioma cells were irreversible or not, U373-MG and Hs683
cells were treated with 100 μM fusicoccin A and were washed after 3,
24, and 48 hours after treatment. The number of viable cells was de-
termined 72 hours after having removed fusicoccin A from the culture
media. Each experimental condition was performed in six replicates.
Computer-assisted Phase-Contrast Microscopy
(Video Microscopy)
Using the human U373-MG GBM cell line, the effects of treatment
with 100 μM fusicoccin A on cell viability and cell division were char-
acterized in vitro by computer-assisted phase-contrast video microscopy
as described elsewhere [25]. The cells were monitored for 72 hours.
114 Fusicoccin-Induced FAK Inhibition in Glioblastoma Bury et al. Translational Oncology Vol. 6, No. 2, 2013
Films were compiled from the obtained time-lapse image sequences,
which enabled a rapid screening of cell viability. Each experimental
condition was performed in triplicate.
Cell count–based determination of global growth ratio. In each
(control or treated) condition, the cell growth rate was evaluated by the
ratio between the number of cells counted in the first and last frames of
the image sequences. The global growth ratio (GGR) was defined as the
ratio between the two growth levels obtained in the treated and control
conditions. All of the cell counts were performed in triplicate using an
interactive computer tool [25,26]. The GGRs were computed at the
24th, the 48th, and the 72nd hour of quantitative video microscopy
analyses by dividing the cell growth rate in fusicoccin A–treated
U373-MG cell populations by the cell growth rate at the same exper-
imental times in the corresponding control U373-MG cell populations.
Specific analysis of cell division rate and duration. Cells under-
going division exhibit very bright patterns compared to nondividing
cells. On the basis of this observation, we developed a custom divi-
sion detection system that is capable of identifying cells undergoing
division in time-lapse sequences. This detection method is based on
an automatic event detection completed by an interactive validation/
correction procedure as previously described [25,26]. At the end of
the sequence analysis, all of the events are linked to different cell
divisions, which reveal the number of cell divisions as well as their
durations [25,26]. We computed the cell division numbers normal-
ized by the number of cells that were counted in the first frame.
Quantitative determination of cell migration. The effect of fusi-
coccin A (100 μM) on cell motility in the U373-MG GBM cell line
was investigated. Figure 5A shows typical analyses based on the indi-
vidual cell trajectories that are established by a cell-tracking algorithm
based on an image series acquired during a cell migration experiment.
The greatest linear distance between a starting point of a cell and the
farthest point reached in its trajectory, also known as the maximum
relative distance from the point of origin (MRDO), was the quantita-
tive variable used to characterize compound-mediated effects on cancer
cell migration [27].
Determination of In Vitro Cell Death
To evaluate viability in U373-MG cells that were treated with fusi-
coccin A, an assay measuring DNA fragmentation was used. The
terminal deoxynucleotidyl transferase–mediated deoxyuridine triphos-
phate nick end labeling (TUNEL) assay was performed according to
a procedure previously described [28,29] using the APO-Direct Kit
(BD Pharmingen, Erembodegem-Aalst, Belgium). The protocol was
performed according to the manufacturer’s instructions, including the
use of positive and negative controls. Briefly, U373-MG GBM cells
were treated with 100 μM fusicoccin A for either 24 or 72 hours in
culture media or left untreated. Adherent and nonadherent cells were
collected, fixed with 1% paraformaldehyde (1 hour) at 4°C, perme-
abilized, and stored in 70% ethanol at −20°C. TUNEL labeling was
performed for 1 hour at 37°C and the stained cells were analyzed
on a CellLab Quanta SC flow cytometer (Beckman Coulter, Analis,
Suarlee, Belgium).
Analyses of Actin Cytoskeletal Organization
U373-MG cells were cultured for 30 hours in the absence (controls)
or presence of 100 μM fusicoccin A on glass coverslips as previously
described [30]. Fluorescent phalloidin conjugated with the Alexa Fluor
488 fluorochrome (Molecular Probes, Invitrogen) was used to label
fibrillar actin, and Alexa Fluor 594–conjugated DNAse I (Molecular
Probes, Invitrogen) was used to stain globular actin. The coverslips
were mounted on microscope slides with 10 μl of Moviol agent
(Calbiochem, VWR, Heverlee, Belgium). Three coverslips per experi-
mental condition were analyzed and three pictures were taken for
each coverslip (with the same exposure time) using an AxioCamHRm
fluorescent microscope (Zeiss, Oberkochen, Germany). The most
representative images are shown in Figure 4B.
Boyden Chamber Assay
The invasive features of U373-MG cells treated with 50 and 100 μM
fusicoccin A for 24 hours in vitro were assessed using the Boyden
transwell invasion system (BD BioCoatMatrigel invasion chambers;
BD Biosciences Discovery Labware, Bedford, MA) as detailed else-
where [31]. In parallel, the same number of U373-MG cells were
seeded in 24-well plates coated with Matrigel, and we treated the cells
with 0 (control), 50, or 100 μM fusicoccin A for 24 hours. To normal-
ize the number of invasive cells, the number of viable cells in each con-
dition was determined. Each experiment was performed in triplicate.
In Vitro Adhesion Assay
The adhesion assay was performed as described previously [31] with
modifications. Briefly, glass coverslips in 24-well plates were precoated
with Matrigel (diluted 1:3 in RPMI culture media with 10% FCS) for
1 hour at 37°C. The wells were washed and nonspecific binding was
then blocked with 0.1% BSA in phosphate-buffered saline for 30 min-
utes. U373-MG cells (20,000 cells per well) were allowed to adhere for
24 hours at 37°C in the presence of either 0 (control), 50, or 100 μM
fusicoccin A, after which nonadherent cells were gently washed away
with warm phosphate-buffered saline. Adherent cells were methanol-
fixed, hematoxylin-stained, and counted in 10 fields per well at a G ×
10 magnification using an Olympus microscope (Olympus, Antwerp,
Belgium). Each experimental condition was performed in triplicate.
Kinase Activity Determination
We originally provided ProQinase (Freiburg, Germany) with fusi-
coccin A as a stock solution in 100%DMSO and aliquots were further
diluted with water in 96-well microliter plates directly before use. A
radiometric protein kinase assay (33PanQinase Activity Assay) was used
for measuring the kinase activity of 288 recombinant protein kinases
as detailed previously [32]. Fusicoccin A was tested in two replicates in
each kinase assay, and the final concentration tested was 50 μM.
Western Blot Analyses
U373-MG cells, either untreated (control) or treated with 25, 50,
or 100 μM fusicoccin A, were incubated under normoxic or hypoxic
conditions (see the Cell Lines, Culture Conditions, and Transfection
section). U373-MG cells were also treated with 100 μM CoCl2 for
4 hours as a positive control for the expression of hypoxia-inducible
factor-1alpha (HIF-1α). Proteins were extracted using the CelLytic
M Cell Lysis Reagent (Sigma) with 1 mM Na3VO4. An equal amount
of cell extract was resolved on a sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) gel and transferred to a polyvinylidene
fluoride (PVDF) membrane. The membranes were blocked with 5%
milk or BSA for at least 1 hour, followed by an overnight incubation
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at 4°C with the following primary antibodies: phosphorylated FAK (di-
luted 1:100; R&D Systems, Minneapolis, MN), FAK (diluted 1:100;
R&D Systems), HIF-1α (diluted 1:200; Abcam, Cambridge, United
Kingdom), and tubulin (diluted 1:5000, Abcam). Secondary antibodies
were purchased from Pierce (Aalst, Belgium) and the blots were ana-
lyzed using the Bio-Rad ChemiDoc XRS Imager and were quantified
with Image Lab (Bio-Rad Laboratories, Nazareth Eke, Belgium). The
experiments were performed in two independent replicates.
Statistical Analysis
The data obtained from two independent groups were compared using
the nonparametric Mann-Whitney U test. The statistical analysis was
performed using Statistica software (StatSoft, Tulsa, OK). When the
number of experiments was less than n = 4, the mean ± SD was used.
Results
Characterization of Fusicoccin A Physicochemical Stability
Figure 1 shows that fusicoccin A [retention time (RT) = 19.5 min-
utes] generates two degradation products when it is maintained at 37°C
for 3 days in MEM culture media. The major degradation product
has been identified (with comparisons to the available standards) as
3′-O-deacetyl fusicoccin (RT = 14.7 minutes) and the minor product
as 19-O-deacetyl fusicoccin (RT = 17.4 minutes) using TLC, HPLC,
ESI-MS, EI-MS, and NMR analyses according to a methodology that
was previously validated [21]. The ESI-MS spectra of these degrada-
tion products revealed a molecular sodium cluster at 661 m/z, which
corresponded to 3′-O-deacetyl fusicoccin A, and sodium/potassium
cluster ions at m/z 661 and 677, which corresponded to 19-O-deacetyl
fusicoccin A, confirmed by the EI- and ESI-MS and 1H NMR. HPLC
analyses revealed that approximately 50% of fusicoccin A remained
after 3 days (D3) at 37°C in MEM (Figure 1B). The in vitro growth
inhibitory activities of fusicoccin A, 3′-O-deacetyl fusicoccin A, and
19-O-deacetyl fusicoccin A were determined by calculating the means
from the MTT colorimetric assay performed on U373-MG and Hs683
glioma cell lines as detailed below.
In Vitro Growth Inhibitory Effect of Fusicoccin A in Normal
versus Cancer Cell Lines
The in vitro growth inhibitory activity of fusicoccin A and its two
degradation products was assayed using an MTT colorimetric assay
on two human glioma cancer cell lines (Figure 2A). The U373-MG
cancer cell line displays varying degrees of resistance to pro-apoptotic
stimuli [33], while the human Hs683 oligodendroglioma cell line
(1p19q co-deleted) displays sensitivity to pro-apoptotic stimuli [34].
The inhibitory effect of fusicoccin A on in vitro growth was also ana-
lyzed in normal astrocytes (Figure 2B). We observed no differences
in terms of sensitivity to fusicoccin A and its degradation products
between the two glioma cell lines with distinct sensitivities to pro-
apoptotic stimuli. We identified the in vitro concentration of each
Figure 2. Anticancer activity of fusicoccin A and its degradation products. (A) Characterization of the in vitro growth inhibitory effects
induced by fusicoccin A, 3′-O-deacetyl fusicoccin, and 19-O-deacetyl fusicoccin in two human glioma cell lines (U373-MG and Hs683).
(B) Characterization of the in vitro growth inhibitory effects induced by 100 μM fusicoccin A 72 hours after having cultured the cancer
cells for 3, 24, and 48 hours before washing out fusicoccin A. (C) Doubling time of U373-MG and Hs683 glioma cells versus normal
astrocytes. (D) Determination of fusicoccin A–related bioselectivity between normal (astrocytes) and tumor (Hs683 and U373-MG) cells
using the MTT colorimetric assay.
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of the three compounds that induced a 50% reduction in growth
(IC50) after culturing the cells for 3 days either in the presence or the
absence (control) of the drug of interest: the IC50 growth inhibitory
concentration of fusicoccin A was 92 μM in the U373-MG cells and
83 μM in the Hs683 glioma cells, whereas the IC50 ranged between 80
and 130 μM for the two degradation products in these two glioma
cell lines (Figure 2A). Therefore, we focused on fusicoccin A and its
potential anti-GBM effects, which become irreversible after 24 hours
of treatment (Figure 2B). For assessment of differential sensitivity be-
tween normal and tumor glial cells to fusicoccin A, normal astrocytes
showing similar doubling time as cancer cells under study were used
(Figure 2C ). We observed that 1 mM fusicoccin A treatment did
not significantly decrease the growth of normal astrocytes, whereas
100 μM fusicoccin A treatment decreased the growth of the two tumor
glial cell lines by approximately 50% (Figure 2D). As the inhibitory
activity of fusicoccin A on in vitro growth was analyzed in human
glioma cell lines while the bioselectivity was determined in normal
mouse astrocytes, we also determined that fusicoccin A inhibited
in vitro growth with an IC50 of ∼70 μM in mouse melanoma
B16F10 cells to rule out differences that could relate to interspecies
features. This result indicates that mouse and human cancer cells dis-
play similar sensitivity to fusicoccin A. Therefore, the bioselectivity
index between normal and tumor astrocytes is >10.
Fusicoccin A Displays Cytostatic Effects through an Increase
in the Duration of Cell Division in GBM Cells
Fusicoccin A induces cytostatic effects in U373-MG GBM cells,
which is demonstrated in Figure 3A. Using quantitative video micros-
copy analyses, we validated the growth inhibitory effects of fusicoccin A
on U373-MG cells that were observed in the MTT colorimetric assay.
Indeed, Figure 3B shows that fusicoccin A–treated U373-MG cells
displayed lower growth kinetic rates over time when compared with
control cells as measured by calculating GGR indices. According to
these GGR index calculations, 100 μM fusicoccin A treatment for
72 hours decreased the in vitro growth rate of U373-MG GBM cells
by approximately 60% (GGR = 0.4). Quantitative video microscopy
analyses also revealed that the growth inhibitory activity of fusicoccin
A was essentially due to cytostatic effects, including a marked decrease
in the mitotic rate of U373-MG GBM cells (Figure 3B) and an in-
creased duration of cell division (Figure 3C). Indeed, the cell division
duration increased by 40 minutes in U373-MG GBM cells over the
Figure 3. Fusicoccin A decreases proliferation of GBM cells. (A) Videomicroscopy–related illustrations of the effects of 100 μM fusicoccin A
on the U373-MG GBM cell line after 72 hours. (B) In vitro global growth rate determination (using the GGR assessment as described in
Materials and Methods section) of fusicoccin A–treated U373-MG cells compared to their control counterparts. (C) The number of cell
division events detected during the 0- to 24-, 24- to 48-, and 48- to 72-hour treatments of U373-MG cells with 100 μM fusicoccin A. The
relative number of divisions is the number of cell divisions counted and normalized by the number of cells counted in the first frame.
(D) The duration of cell division events detected during the 0- to 24-, 24- to 48-, and 48- to 72-hour treatments of U373-MG cells with
100 μM fusicoccin A. The data are reported as the median values ± the 25th to 75th percentiles calculated in triplicate.
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72-hour period of 100 μM fusicoccin A treatment compared to control
cells (P < .001).
Fusicoccin A–treated U373-MG GBM Cells Display Marked
Modifications in the Actin Cytoskeletal Organization and
Few Cell Deaths Only
The morphologic changes observed in Figure 4A (a arrows) show an
elongated morphology of the U373-MG cells, suggesting cytoskeletal
changes. Fluorescence microscopy analyses confirmed that fusicoccin A
induced modifications in the actin cytoskeletal organization in these
cells (Figure 4B). Indeed, the levels of polymerized actin (green fluo-
rescence) increased in U373-MG GBM cells after 30 hours of 100 μM
fusicoccin A treatment (Figure 4B). In contrast, as morphologically
illustrated in Figure 4A (b arrows), few cell deaths occur over the
72-hour period of fusicoccin A treatment as confirmed by flow
cytometry (FCM)/TUNEL analyses. The data in Figure 4C show
that fewer than 20% of the U373-MG cells treated with 100 μM
fusicoccin A for 72 hours underwent DNA degradation processes.
Fusicoccin A Affects the Migration Characteristics of
U373-MG GBM Cells
The dynamic organization of the F-actin cytoskeleton and the
regulation of focal adhesion assembly and disassembly are essential
processes required for efficient movement in cell migration. There-
fore, we analyzed the effects of fusicoccin A on the migration of
U373-MG cells. As shown in Figure 5, A and B (quantitative video
microscopy), fusicoccin A decreased both two-dimensional and three-
dimensional (Figure 5, C and D; Boyden chamber assay) migration
features of U373-MG GBM cells. The reduction in the number of
invading cells was not due to a decrease in cell proliferation or cyto-
toxicity because 1) as shown in Figure 5D, the number of invading
cells was normalized by the number of living cells counted in both the
control and fusicoccin A–treated conditions after a 24-hour period and
2) we show that fusicoccin A also decreased the adhesion of U373-MG
cells cultured on Matrigel in a dose-dependent manner (Figure 5,
E and F ).
Fusicoccin A Inhibits the Activity of Various Kinases,
Including FAK
Actin cytoskeletal organization and the invasive and adhesive charac-
teristics of cells, in particular GBM cells, depend on multiple signal-
ing pathways, including various protein kinases [35,36]. At 50 μM, a
concentration we tested in the invasion and adhesion assays (Figure 5)
that is weaker than the in vitro IC50 growth inhibitory concentrations
(92 μM in U373-MG and 83 μM in Hs683 glioma cells), fusicoccin A
decreased the activities of 13 (Figure 6A) of 288 kinases analyzed by
50%, especially tyrosine kinase (Figure 6B). As detailed later in the
Discussion section, of these 13 kinases targeted by fusicoccin A, we
Figure 4. Fusicoccin A is a cytostatic compound. (A) The panel represents illustrations of the morphologic changes of U373-MG cells
treated with 100 μM fusicoccin A after 30 and 72 hours compared to the untreated cells; a arrows represent the elongation of U373-MG
cells treated with fusicoccin A after 30 hours and b arrows indicate dead cells after 72 hours. (B) Fluorescence microscopy was employed
to visualize the fibrillar (polymerized) actin in green and the globular (unpolymerized) actin in red. The effects of 100 μM fusicoccin A were
monitored during 30 hours and compared to untreated cells. (C) FCM-related analyses (TUNEL) of the percentages of apoptotic U373-MG
GBM cells that were treated for 24 and 72 hours with 100 μM fusicoccin A. The positive and negative controls were furnished by the manu-
facturer of the TUNEL kit and are presented above the graph. The data are reported as the mean values ± SD calculated in triplicate.
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focused specifically on FAK because 1) it is an important player in the
acquisition of the aggressive phenotype of GBM cells and 2) our data
show FAK’s potential implication in the defect of cell adhesion
(Figure 5E). Moreover, FAK is implicated in proliferation, morphology
modification, migration, invasion, adhesion, angiogenesis, and cancer
cell survival features [37–44].
Fusicoccin A Inhibits FAK Phosphorylation of U373-MG
GBM Cells in Both Normoxic and Hypoxic Conditions
FAK is activated by autophosphorylation of tyrosine 397, which
is necessary for FAK-induced cell invasion [37–40]. To determine
whether FAK is involved in the fusicoccin A–induced inhibition of
U373-MG cell invasion and adhesion, we performed immunoblot
Figure 5. Fusicoccin A decreases migration of GBM cells. (A) The evaluation of the antimotility activity of fusicoccin A in U373-MG GBM
cells. The motility of individual cells treated with 100 μM fusicoccin A for 24 hours was quantified by establishing the trajectory of each cell
centroid and by quantifying the MRDO variable (the maximum distance covered by a cell and normalized by its observation time, expressed
in μm/h). (B) The distribution of MRDO values obtained for U373-MG cells treated with 100 μM fusicoccin A for 24 hours compared to the
untreated cells. The data are reported as the median values ± the 25th to 75th percentiles calculated in triplicate. (C) The panel represents
illustrations of the U373-MG invasive cells that were either untreated or treated with 50 or 100 μM fusicoccin A for 24 hours. (D) Quan-
tification of the in vitro invasive activity of U373-MG cells either untreated or treated with fusicoccin A in Boyden chambers coated with
Matrigel. The cells that penetrated through the Matrigel to the lower surface of the filters were stained. The number of invasive cells was
counted in 10 fields per chamber (the chamber surface includes 30 fields), and the experiment was conducted in triplicate. The sum of the
10 values was used to calculate the percentage of invasive cells in the population, and the control invasion rate was normalized to the
number of counted cells as 100%. We also normalized the invasion rate by the number of counted cells treated with 50 and 100 μM fusi-
coccin A. The results are expressed as the mean values ± SD calculated in triplicate. (E) Quantification of the in vitro adhesive activity of
U373-MG cells that were either untreated or treated with fusicoccin A. The cells that adhered on Matrigel supports were stained and then
determined by microscopy. The number of adhesive cells was counted in 10 fields per glass coverslip and the experiment was conducted
in triplicate. The sum of the 10 values was used to calculate the percentage of adhesive cells in the population, and the control adhesion rate
was reported to be 100%. The results are expressed as the mean values ± SD calculated in triplicate. (F) The panel represents illustrations
of the U373-MG adhesive cells either untreated or treated with 50 or 100 μM fusicoccin A for 24 hours.
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experiments using a phosphorylation-specific antibody against FAK
in both normoxic and hypoxic cell culture conditions. We analyzed
FAK activity in both normoxic and hypoxic conditions because it has
been previously shown that the activated form of FAK is increased in
GBM cells grown in hypoxic conditions [43] [see also phosphorylated
focal adhesion kinase (pFAK) signals in normoxic versus hypoxic con-
ditions in untreated cells in Figure 7C].
First, we determined whether the in vitro IC50 of fusicoccin A in
U373-MG cells (as determined above) differed in normoxic versus
hypoxic conditions. As shown in Figure 7A, this was not the case. In
addition, as shown in Figure 7C , at concentrations ranging from 25 to
100 μM, fusicoccin A reduced FAK phosphorylation at tyrosine 397
under both normoxic and hypoxic conditions in a dose-dependent
manner.We also verified that hypoxic conditions were actually induced
in U373-MG GBM cells by confirming the increase in HIF-1α expres-
sion in GBM cells maintained under 1% O2 conditions (Figure 7B).
FAK Overexpression in U373-MG Cells Reduces
Fusicoccin A–Induced Growth Inhibition
To confirm that FAK is actually associated with the in vitro growth
inhibitory activity of fusicoccin A, U373-MG cells were transfected
with pCMV6-PTK2 (FAK) or with pCMV6-XL4 (control) and then
their growth levels in the presence or the absence (control) of fusicoccin
A was evaluated by means of the MTT colorimetric assay. FAK over-
expression after transfection was confirmed by Western blot analysis
(Figure 7D). As shown in Figure 7E , FAK overexpression in U373-MG
cells reduced by about two times the in vitro growth inhibitory effects
induced by fusicoccin A.
Discussion
GBM is currently an incurable disease with a median survival time of
approximately 15 months [3]. The search for low–molecular weight
drugs that target growth-related kinases, especially tyrosine kinases,
has become an attractive area of research that aims to identify new
therapies that can extend the survival and standard of life of patients
with cancer [36]. In this report, fusicoccin A was identified as an inhib-
itor of several kinases, including FAK. Because FAK is a key molecule
that is necessary for cell proliferation, migration, angiogenesis, and
invasion during cancer progression [37–44], FAK, in addition to other
kinases implicated in the control of the actin cytoskeletal organization,
could potentially be a target in GBMs [45].
In the current study, the anticancer activity of fusicoccin A, a
phytotoxic carbotricyclic diterpene glucoside of fungal origin, was char-
acterized in glioma cells. First, we analyzed whether fusicoccin A dis-
plays bioselectivity between normal and tumor glial cells, and the data
clearly indicated that the bioselectivity level is at least above 10. The
bioselectivity of fusicoccin A therefore suggests that it could be used
to target cancer cells alone, with minor effects on normal surrounding
tissues. In addition, we observed the same in vitro sensitivity to fusi-
coccin A on two glioma cell lines despite their different levels of resis-
tance to pro-apoptotic stimuli. The fact that fusicoccin A overcomes,
at least partly, the intrinsic resistance of GBM cells to pro-apoptotic
stimuli relates to the cytostatic, not cytotoxic, properties of this com-
pound. Indeed, we demonstrated that the fusicoccin A–induced growth
inhibitory effects in malignant glioma cells are related to an increase in
the duration of cell division.
Fusicoccin A–induced cytostatic effects occur through modifica-
tions of actin cytoskeletal organization, a feature that, in turn, can be
explained in part by the fact that fusicoccin A inhibits the activity of
several kinases necessary for controlling actin cytoskeletal organization.
Indeed, inhibiting various protein kinases, such as FAK and ephrins
(four of them are targeted by fusicoccin A; Figure 6A), perturbs Rho
GTPase signaling and therefore alters actin cytoskeletal organization
through the Rho/ROCK-dependent formation of actin stress fibers
[46,47]. Lamalice et al. demonstrated that the activation of the tyrosine
kinase receptor, vascular endothelial growth factor receptor 2 (also tar-
geted by fusicoccin A; Figure 6A), by vascular endothelial growth factor
leads to actin polymerization and reorganization into stress fibers in
endothelial cells [48]. Another kinase inhibited by fusicoccin A is C-Src
kinase (CSK), which plays a critical role in mediating G-protein signal-
ing in actin cytoskeletal reorganization [49]. Therefore, the majority of
the dozen of kinases impaired by fusicoccin A (Figure 6A) are tyrosine
Figure 6. Characterization of fusicoccin A–induced anti-kinase ac-
tivity. (A) In vitro anti-kinase profiles of fusicoccin A. The data are
presented as the means ± SD values calculated in duplicate. (B) A
schematic illustration of the kinases in the human dendrogram-
related kinome that were targeted at 50 μM fusicoccin A with analy-
sesof<50%of kinase residual activity. Thevariousclasses of kinases
included tyrosine kinases (TK), tyrosine kinase–like kinases (TKL),
serine/threonine protein kinases (STE), casein kinases (CK1), cyclic
adenosine monophosphate (cAMP)–dependent protein kinases
(AGC), calcium/calmodulin protein kinase II kinases (CAMK), and the
CMGC subclass, which includes cyclin-dependent kinase, MAPK,
glycogen synthase kinase, and cyclin-dependent kinase–like groups
of kinases.
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kinases (Figure 6B), which are involved in the migratory and invasive
features of malignant glioma cells [44,46,50–53].
Of the various kinases that are impaired by fusicoccin A, we focused
on FAK, which is a nonreceptor cytoplasmic tyrosine kinase that is
recruited at an early stage to focal adhesions [39]. Various stimuli
can induce activation of FAK by autophosphorylation on a particular
tyrosine residue, Y397, including integrin and growth factor receptor
engagement [39]. Activated FAK creates a high-affinity binding site
for Src homology 2 domain–containing proteins that subsequently
interact with a number of downstream signaling proteins such as the
adaptor protein Grb2 and PI3K [37,39]. Consequently, FAK plays
a critical role in malignant GBM cell behavior because it is involved
in the regulation of GBM cell growth and survival through the acti-
vation of the PI3K/AKT/mammalian target of rapamycin (mTOR)
and the extracellular signal–regulated kinase/MAPK signaling pathways
[2,37]. Furthermore, several studies report that FAK is overexpressed in
cancer cells, including GBM cells, and that the status of FAK correlates
with tumor progression and poor clinical outcomes [44,54]. On the
basis of the central function of FAK and its ability to regulate different
pathways implicated in dismal prognosis of GBM, FAK represents a
target of interest, which is further reinforced by the failure of receptor
tyrosine kinase inhibitors.
In GBMs, necrotic foci are surrounded by “pseudopalisading” cells,
which are severely hypoxic [55]. Hypoxia in GBM is correlated with
aggressiveness and invasiveness by the switch in metabolism, resistance
to apoptosis, and neovascularization. All of these phenomena induce
Figure 7. Characterization of fusicoccin A–induced anti-kinase activity, with a focus on FAK. (A) Determination of the in vitro IC50 of fusi-
coccin A in U373-MG cells cultured under normoxic and hypoxic conditions using the MTT colorimetric assay. The data are reported as
the mean values ± SD calculated in triplicate. (B) U373-MG cells were incubated under normoxic versus hypoxic conditions for 24 hours.
CoCl2-treated U373-MG cells were used as a positive control for HIF-1α expression. Total cell lysates were resolved on SDS-PAGE
and immunoblotted with the anti–HIF-1α antibody. (C) U373-MG cells either untreated or treated with 25, 50, or 100 μM fusicoccin A
for 24 hours were incubated under normoxic or hypoxic culture conditions. Total cell lysates were resolved on SDS-PAGE and immuno-
blotted with anti–pFAK, total anti-FAK, and anti-tubulin antibodies. The Western blot bands have been digitized, and quantitative data
below the Western blot bands represent the number of pixels of the pFAK band multiplied by pixel intensity, the final result of which
has been normalized to the corresponding tubulin band. (D) Immunoblot analysis demonstrated FAK overexpression in U373-MG cells when
transfected with pCMV6-PTK2 (FAK); pCMV6-XL4 was used for control. The Western blot bands have been digitized, and quantitative
data below the Western blot bands represent the number of pixels of the FAK band multiplied by pixel intensity, the final result of which
has been normalized to the corresponding tubulin band. (E) Characterization of the in vitro growth inhibitory effects induced by fusicoccin A
in U373-MG cells transfected with pCMV6-XL4 (control) and pCMV6-PTK2 (FAK).
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the apparition of TMZ resistance in hypoxic areas [56]. Furthermore,
GBM cells are maintained by cancer stem cells that are inherently
radiotherapy and chemotherapy resistant and may be preserved in vivo
in a niche characterized by hypoxia [57,58]. Thus, testing fusicoccin A
in different in vitro and in vivo models containing cancer stem cells, to
prove the activity of our molecule on this subtype of cells, would
be interesting. Moreover, Skuli et al. [43] have also shown that the
integrin/FAK pathway is involved in hypoxic regulation in GBMs. In
our report, we found that the hypoxic state of GBM cells does not
impair in vitro fusicoccin A–induced growth inhibitory activity or its
inhibitory effects on FAK activity.
Finally, it should be emphasized that the coefficient partition of
fusicoccin A in hydrophilic/lipophilic solutions is more favorable than
that of most natural antitumor compounds. Indeed, the theoretical pre-
dicted log P value (software calculation) of fusicoccin A is 3.4, which
suggests that this compound should be able to cross the blood-brain
barrier without the need to tremendously adapt its formulation.
In conclusion, this report identifies fusicoccin A, a fungal metabolite,
as an in vitro cytostatic and antimigratory compound in human GBM
cells that display varying degrees of resistance to pro-apoptotic stimuli.
Importantly, fusicoccin A maintains its therapeutic activity in target-
ing FAK, at least partly, even under hypoxic conditions and displays
bioselectivity between normal and tumor glial cells. Altogether, these
data open new perspectives for GBM treatment and in particular
warrant further studies examining the in vivo effects of fusicoccin A
on TMZ-resistant brain tumors.
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